Meta-Analysis Comparing Percutaneous Closure Versus Medical Therapy for Patent Foramen Ovale

Patent foramen ovale (PFO) is the most common congenital heart defect with an estimated prevalence of 1 in 4 adults. The optimal treatment strategy for patients with PFO with cryptogenic stroke has long been debated. Early clinical trials, including Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT) (NCT00465270), Patent Foramen Ovale and Cryptogenic Embolism (PC) (NCT00166257), and Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale (CLOSER) I (NCT00201461), did not show benefit for PFO closure in the reduction of recurrent embolic stroke and/or systemic embolism compared with medical therapy.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research